NEJM Group

CardioExchange Archive

CardioExchange, an NEJM practice community for medical professionals dedicated to improving cardiac patient care, was active from 2009 to 2015. CardioExchange fostered discussion between clinicians from across the globe.

March 28th, 2014

ACC.14 Headquarters

wpengine

CardioExchange is dedicated to bringing you the latest from ACC.14. Check out our coverage of the conference ─ and some of the great debates these posts have sparked ─ then tell us what you think!

News:

  • No Benefit Found in First Real Test of Renal Denervation
  • Survival Advantage for TAVR Over Surgery in High-Risk Patients
  • First TAVR Comparison Trial Favors Sapien XT Over CoreValve
  • MADIT-CRT Long-Term Follow-Up Shows Survival Benefit with CRT-D
  • High-Sensitivity Troponin Test Could Identify Low-Risk Chest Pain Patients in the ED
  • Aspirin and Clonidine Fail to Help Surgery Patients
  • Novartis Trial Was Stopped Early Because of a Significant Drop in Cardiovascular Mortality

Analysis:

  • Negative Findings on Renal Denervation for Hypertension: Sweet SYMPLICITY?
  • TAVR: Are You Impressed Now?
  • Long-Term Follow-Up from MADIT-CRT: Guideline Implications
  • Are We Equipped to Make a CHOICE Between TAVR Devices?

Follow our Fellows:

  • Changing My Priorities for ACC.14
  • Ideals Lost, But Not Stolen
  • Are Digital Conferences the Way of the Future?
  • Taking Patient-Centerdness to the Next Level at ACC.14
  • Stage Set for Phase IV Trials of PCSK9 Inhibition
  • Master of all Trades

Categories: General


You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.

  • Search the Archive

  • Archives by Date

  • RSS NEJM — Recent Cardiology Articles

    • Endovascular Therapy for Medium-Vessel Occlusion Stroke — Narrowing the Target Population May 14, 2026
      One way to classify acute ischemic stroke is by the anatomy of vessel occlusion. Initial randomized trials of endovascular thrombectomy focused on large-vessel occlusions.1-5 These proximal occlusions of the intracranial carotid artery or the stem of the middle cerebral artery (MCA) represent the most severe form of anterior...
    • Central Retinal-Vein Occlusion May 14, 2026
      A 65-year-old woman with cardiovascular risk factors presented with a 14-hour history of painless, worsening, blurry vision in the right eye (visual acuity, 20/400). Funduscopy showed diffuse retinal hemorrhages and venous dilatation.
    • Endovascular Treatment of Medium-Vessel-Occlusion Strokes May 14, 2026
      Among patients with stroke due to medium-vessel occlusion, thrombectomy led to functional independence at 90 days (in 58.6% of patients, vs. 46.6% with medical management) but also to a higher risk of intracranial hemorrhage.
    • Double Take: HFpEF Explained — Living with HFpEF May 7, 2026
      This patient-focused Double Take video describes heart failure with preserved ejection fraction and how it is managed.
    • Price of Protection — Microaxial Flow Pump in High-Risk PCI May 7, 2026
      In the catheterization laboratory, the most consequential decisions are frequently not about whether to treat, but rather about how far to extend treatment. Nowhere is that tension more apparent than in high-risk percutaneous coronary intervention (PCI). In these cases, the margin between a good outcome and a catastrophic one is...
  • Tag Cloud

    • ACS AF AHA anticoagulation aortic valve replacement apixaban aspirin atrial fibrillation CABG cardiovascular risk cholesterol clopidogrel dabigatran diabetes diet drug-eluting stents epidemiology ESC exercise FDA FDA approvals Fellowship training guidelines HDL heart failure hypertension ICDs MI myocardial infarction obesity PCI Primary PCI risk factors rivaroxaban statins STEMI stents stroke stroke prevention TAVI TAVR type 2 diabetes venous thromboembolism warfarin women
NEJM Group

Copyright © 2026 Massachusetts Medical Society. All rights reserved.

The content of this site is intended for health care professionals. Copyright | Terms | Privacy Policy |